Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < 0.0001 vs ... Figure 1. Mean change in BW (kg)

Published byKaare Eriksen Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < 0.0001 vs ... Figure 1. Mean change in BW (kg)"— Presentation transcript:

1 Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < vs ... Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < vs comparator. Based on “on-treatment without rescue medication” data from subjects in the full analysis set. Mean change in BW was estimated using a mixed model for repeated measurements that included treatment, country, and baseline BW as variables, all nested within visit. n: number of subjects with valid observation at landmark visit; N: full analysis set. MET, metformin; TZD, thiazolidinedione. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2019 Endocrine Society None, Volume 104, Issue 9, 02 April 2019, Pages 4078–4086, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Change in IR from baseline to end of treatment in (a) SUSTAIN 1, (b) SUSTAIN 2, and (c) SUSTAIN 3 by ... Figure 2. Change in IR from baseline to end of treatment in (a) SUSTAIN 1, (b) SUSTAIN 2, and (c) SUSTAIN 3 by weight-change category. Based on “on-treatment without rescue medication” data from subjects in the full analysis set, with missing data imputed from a mixed model for repeated measurements. Weight-change categories were chosen to ensure sufficient subject numbers in each group. Relative change from baseline in HOMA-IR (%) was calculated from the geometric mean ratio to baseline. Values were analyzed on a logarithmic scale and back-transformed into the original scale. Dashed lines represent change in WL category. n: subjects contributing to summary; N: full analysis set. MET, metformin; TZD, thiazolidinedione. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2019 Endocrine Society None, Volume 104, Issue 9, 02 April 2019, Pages 4078–4086, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Relationship between BW and IR in (a) SUSTAIN 1, (b) SUSTAIN 2, and (c) SUSTAIN 3. “On-treatment without ... Figure 3. Relationship between BW and IR in (a) SUSTAIN 1, (b) SUSTAIN 2, and (c) SUSTAIN 3. “On-treatment without rescue medication” data are shown, with missing data imputed from a mixed model for repeated measurements. Dotted lines show regression lines fitted for each treatment separately on log-transformed IR values. Regression equations for SUSTAIN 1: semaglutide 0.5 mg y = e<sup>0.0352x</sup>, semaglutide 1.0 mg y = e<sup>0.0324x</sup>, placebo y = e<sup>0.0431x</sup>; for SUSTAIN 2: semaglutide 0.5 mg y = e<sup>0.0467x</sup>, semaglutide 1.0 mg y = e<sup>0.0486x</sup>, sitagliptin y = e<sup>0.0141x</sup>; for SUSTAIN 3: semaglutide 1.0 mg y = e<sup>0.043x</sup>, exenatide ER y = e<sup>0.0334x</sup>. The y-axes scales are logarithmic. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2019 Endocrine Society None, Volume 104, Issue 9, 02 April 2019, Pages 4078–4086, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Improvement in insulin resistance at end of treatment mediated, or not mediated, by weight change. Based on ... Figure 4. Improvement in insulin resistance at end of treatment mediated, or not mediated, by weight change. Based on “on-treatment without rescue medication” data from subjects in the full analysis set, with missing data imputed from a mixed model for repeated measurements. The effects were estimated using an imputation-based mediation analysis (18). Mean estimates and 95% CIs are calculated on log-scale and back-transformed to original scale. N/A, not applicable. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2019 Endocrine Society None, Volume 104, Issue 9, 02 April 2019, Pages 4078–4086, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < 0.0001 vs ... Figure 1. Mean change in BW (kg)"

Similar presentations

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.
Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)
Figure 1 The study area within Vienna Zoo is outlined in red

Figure 1 The study area within Vienna Zoo is outlined in red
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Top: Annual modal paternity distance (PDc) estimated for each of 23 cohorts by MasterBayes ... Figure 1 Top: Annual modal paternity distance (PDc)

Figure 1 Top: Annual modal paternity distance (PDc) estimated for each of 23 cohorts by MasterBayes ... Figure 1 Top: Annual modal paternity distance (PDc)
Figure 4 ROMs have a morph-specific effect relative to active aggression but not display behavior in dominant males. ... Figure 4 ROMs have a morph-specific.

Figure 4 ROMs have a morph-specific effect relative to active aggression but not display behavior in dominant males. ... Figure 4 ROMs have a morph-specific.
Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.

Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
FIGURE 1 PRISMA flow diagram of studies in systematic review

FIGURE 1 PRISMA flow diagram of studies in systematic review
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.

Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.
Figure 1 Relationships between magnitude of antithrombotic benefit vs

Figure 1 Relationships between magnitude of antithrombotic benefit vs
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...

Similar presentations

Ads by Google